ANTINEOPLASTIC EFFECT OF NICLOSAMIDE ON EXPERIMENTALLY INDUCED COLORECTAL CANCER IN RATS

SAMAR S. KHALAF 1; SARY K.H. ABD-ELGHAFFAR 1,2 AND MARWA F. ALI 1

1 Department of Pathology and Clinical Pathology, Faculty of Vet. Med., Assiut University.
2 Department of Pathology and Clinical Pathology, School of Vet. Med., Badr University.

Received: 15 April 2024; Accepted: 30 May 2024

ABSTRACT:

An essential research tool for studying colorectal cancer (CRC) is the use of 1, 2-dimethylhydrazine (DMH) as an animal model of colorectal carcinogenesis. Niclosamide (Nic), an oral anthelmintic drug, has been identified as a possible anticancer agent. The purpose of this research was to determine the potential antineoplastic effect of Nic on induced colorectal carcinogenesis. Five groups from thirty-five albino rats were created. Group I was given a vehicle for four weeks. Group II was administered Nic I/P at a dose of 20 mg/kg b.w. daily for four weeks. Group III was administered DMH S/C at a dose of 20 mg/kg b.w. twice weekly for four weeks. Group IV received DMH in the same manner as Group III, and following a week from the last DMH injection, they were given daily doses of 20 mg/kg b.w. of Nic I/P until the experiment concluded. Group V received DMH in the same manner as Group III, and following a week from the last DMH injection, they were given daily doses of 20 mg/kg b.w. of Nic I/P at a dose of 20 mg/kg b.w. twice weekly and Nic I/P at a dose of 20 mg/kg b.w. daily. Upon completion of the experiment, which lasted 12 weeks, rats were sacrificed for sampling. Colon sections of rats in all groups were collected for aberrant crypt foci (ACF) counting using 0.2% methylene blue. Then tissue specimens were taken for histopathological examination. According to the topographical features of colon preneoplastic lesions, we found that group III had more ACF count and crypt multiplicity, whereas groups IV and V had a significantly lower number. Microscopically, rats receiving DMH exhibited moderate to severe dysplastic changes. These changes were significantly decreased in both Nic-treated groups, however, Group V showed the best improvement. These results indicated the obvious protective effect of Nic against ACF progression.

Keywords: Colorectal carcinogenesis; DMH; Niclosamide; ACF; histopathological changes.

INTRODUCTION:

Rectal and colon cancers are anatomically similar, thus in many epidemiological studies they are referred to as colorectal cancer (CRC) (Thyne, 2020). CRC is a malignant tumour originating from the mucosal-lining colonic epithelial cells. It is the second-most lethal and third-most prevalent type of cancer globally (Miller et al., 2016). Even though colon cancer mortality has decreased recently, the disease’s incidence is still increasing (Siegel et al., 2014; Zahid and Young 2016). Numerous risk factors have been linked to CRC development, including inflammatory bowel

Corresponding author: Samar S. Khalaf
E-mail address: samar_soliman@vet.aun.edu.eg
Present address: Department of Pathology and Clinical Pathology, Faculty of Vet. Med., Assiut University
illness, first-degree relatives' history of colorectal polyps or colorectal cancer, advancing age, certain hereditary syndromes (familial adenomatous polyposis) “FAP” and Lynch syndrome (Hereditary non-polyposis colorectal cancer) “HNPCC” and environmental risk factors such as a rise in body mass index (obesity), and dietary habits (low-fiber and high fat-diet) (Johnson et al., 2013; Norat et al., 2014). Over the past decades, numerous murine models of colon carcinogenesis have been developed. The most commonly utilized model of chemically induced colon carcinogenesis is the 1,2-dimethylhydrazine (DMH) model. The electrophilic methyl diazonium ion produced by the metabolism of this carcinogen eventually leads to the creation of carbonium ion, which methylates DNA and other biomolecules of colon epithelial cells (Hussein et al., 2013), hence causing procarcinogenic events brought on by mutations, inflammation and tumour promotion (Siddique et al., 2017; Senedese et al., 2019). It is believed that aberrant crypt foci (ACF), which are preneoplastic lesions, are biomarkers of colon carcinogenesis that identify the early stages of the disease before tumours develops. Their existence can therefore be utilized as the primary endpoint in short-term studies when investigating pharmacological or dietary approaches for colon cancer prevention (Strimbu & Tavel, 2010). Under a microscope at low magnification, they can be distinguished from neighboring crypts by their larger size, somewhat elevated from the surrounding normal mucosa, oval-shaped slit-like opening, and stained darker due to thicker epithelium (Chiou et al., 2010). Histologically, ACF are known as colorectal intraepithelial lesions (Boivin et al., 2003; Tanaka, 2009). The Repurposing Drugs in Oncology (ReDO) project has identified a variety of antiparasitic medications as high-potential agents (Hu et al., 2013). Niclosamide (Nic) is one of these medications, as reported by Wang et al. (2009). Niclosamide (Arend et al., 2016) which has several systematic chemical names such as (5-chloro-N-2-chloro-4-nitrophenyl-2-hydroxybenzamide) is an oral anthelmintic drug that has been approved by the United States Food and Drug Administration (US FDA) for treating most tapeworm infections in human and livestock for approximately 50 years (Andrews et al., 1982; Al-Hadiya 2005). Niclosamide has been identified as a possible anticancer agent that targets molecular pathways involved in carcinogenesis, progression and metastasis of CRC in both in vivo and in vitro models (Li et al., 2014; Satoh et al., 2016), including the Wnt/β-catenin (Londono-Joshi et al., 2014), mTORC1 (Balgi et al., 2009; Wieland et al., 2013), Stat3 (You et al., 2014; Arend et al., 2016), NF-kB (Jin et al., 2010; Wieland et al., 2013), and Notch signaling pathways (Wang et al., 2009; Wieland et al., 2013). Many cancer cells have either mutations, overexpression or constitutive activation of the signaling molecules involved in these pathways (Li et al., 2014).

Therefore, our study was conducted to confirm and evaluate the anticancer effect of Nic on colon carcinogenesis in a DMH-induced colon cancer animal model and to demonstrate Nic as a viable therapeutic option for colon cancer in clinical trials.

MATERIALS AND METHODS:

Materials:

Chemicals:

1. 1. 2-dimethylhydrazine (DMH), Niclosamide (5-chloro-N-2-chloro-4-nitrophenyl-2-hydroxybenzamide), Dimethyl sulfoxide (DMSO), and polyethylene glycol 400 (PEG 400) were purchased from Sigma Chemical Company (St Louis, MO, USA).

2. Immediately before usage, DMH was dissolved in a 0.9% NaCl solution, and 1 mM NaOH was used to adjust the pH to 6.5 (Sugihara et al., 2017).

3. Niclosamide was prepared weekly in 40% (v/v) polyethylene glycol 400 containing 5% (v/v) DMSO (Yang et al., 2016).

Animals:
Male albino rats (n=35) aged 6–8 weeks with body weights of 130 ± 20 gm were purchased from the Animal House of the Faculty of Veterinary Medicine at Assiut University. Healthy circumstances were maintained for them in metal cages, with a temperature of 22°C ± 2 °C and a humidity of 50% ± 5%. They had unrestricted access to food and water and were kept in a cycle of natural light and darkness. The animals were cared for and treated in accordance with the ethical standards for experimental animals as set forth by the Animal House of Assiut University. This study has been approved by the ethical committee of the Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt, according to the OLE standards for the use of animals in research under No. 06/2024/0155.

**Methods:**

**Induction of colon carcinogenesis:**

The rats were administrated 20 mg of DMH per kg of body weight (Okda et al., 2014). Just prior to usage, DMH was weighed and dissolved in 0.9% NaCl. Each rat was given 0.5 ml of the dissolved DMH (El-Deek et al., 2022). DMH was subcutaneously injected twice weekly for four weeks (Okda et al., 2014).

**Experimental Design:**

Rats in each group were weighed once a week in order to determine the dosage of Nic and DMH. The following design was used to randomly divide the rats into five groups:

4. **Group I (Control) (n=7):** Rats were subcutaneously injected with 0.5 ml of 0.9% NaCl (the DMH vehicle) twice weekly for four weeks.

5. **Group II (Nic group) (n=7):** Rats received intraperitoneal injections of Nic at a dose of 20 mg/kg b.w. per day for the first 4 weeks of the experiment (Osada et al., 2011; Moskaleva et al., 2015; Sugihara et al., 2017; Luo et al., 2019).

6. **Group III (DMH group) (n=7):** Rats were subcutaneously injected with DMH at a dose of 20 mg/kg b.w. twice weekly for the first 4 weeks, and then rats were kept without any treatment until the end of the experiment.

7. **Group IV (post-initiation) (DMH followed by Nic group) (n=7):** Rats were subcutaneously injected with DMH at a dose of 20 mg/kg b.w. twice weekly for the first 4 weeks. After 1 week of the last DMH injection, they were given daily doses of 20 mg/kg b.w. of Nic intraperitoneally until the end of the experiment.

8. **Group V (initiation) (DMH + Nic group) (n=7):** Rats were subcutaneously injected with DMH at a dose of 20 mg/kg b.w. twice weekly in conjunction with intraperitoneal injections of Nic at a dose of 20 mg/kg b.w. daily for the first 4 weeks. They were then left without any treatment until the end of the experiment.

At the end of the study after 12 weeks, rats were sacrificed for sampling.
Determination of aberrant crypt foci (ACF) in whole mount colon:
Immediately after the rats were sacrificed, the colons were extracted, flushed with cold saline (0.9% NaCl) to eliminate any fecal contents, and opened along the longitudinal median from the anus to the caecum. Following the excision of the cecum, the remaining colon was divided into three segments, each measuring eight centimeters. These segments were named the proximal colon, which was located next to the cecum; the middle colon; and the distal colon, which was located next to the rectum. Since the middle and distal colons contained the majority of the ACF (Rodrigues et al., 2002; Perše & Cerar, 2011), they were divided into small sections and fixed flat in Styrofoam using 10% buffered formalin, leaving the mucosal surface exposed for 24 hours. Following fixation, colon segments were washed and stained for 15 to 30 minutes at room temperature using a 0.2% methylene blue solution in PBS (Verma & Shukla, 2013). Then, they were placed on a glass slide with the luminal side facing up and examined under a light microscope at 4 and 10× magnifications (Ochiai et al., 2005; Sugihara et al., 2017). The elliptical-shaped opening, darker staining, larger size and slight elevation from the surrounding normal mucosa allowed ACF to be distinguished from neighboring crypts (Rodrigues et al., 2002; Chiou et al., 2010).

Scoring of ACF:
Each rat in each of the experimental groups had their total number of ACFs and ACs calculated (Bird 1998), and each rat’s crypt multiplicity (AC/ACF), which indicated how many crypts were in each focus, was then recorded (Balaji et al., 2015).

Histopathological examination:
Following ACF recording, the 10% buffered formalin-fixed colon segments were processed and sectioned perpendicular to the muscularis mucosa at a thickness of 4-6 μm to visualize the entire length of the crypts, and stained with hematoxylin and eosin (H&E) according to conventional procedures (Bancroft & Gamble, 2008; Suvarna et al., 2018). The slides were inspected using a light microscope at 100 and 400x magnification to determine the type of ACF through histological examination (Verma & Shukla, 2013; Muthu et al., 2016). In accordance with Siu et al., (1997), the material was also examined for the existence of dysplasia and its degree

Histopathological scoring:
Six random fields (400x magnification) were examined in seven rats from each group to score all the microscopic lesions of the H & E-stained colon sections using a semi-quantitative scale from 0 to 3 based on the following histological criteria described in previous reports (Thorup, 1997; Paulsen et al., 2005; Lu et al., 2008):

The histopathological scores (0 = no lesions / normal crypts), (1 = hyperplastic or non-dysplastic crypts), (2 = mild to moderate dysplastic crypts) and (3 = moderate to severe dysplastic crypts) were shown in Table 1.
Table 1: The histopathological scores of aberrant crypts.

<table>
<thead>
<tr>
<th>Crypts</th>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>For normal crypts:</td>
<td>0</td>
<td>It indicates the normal colon histology, which is identified by tightly packed, straight tubular crypts that reach down to the muscularis mucosa and contain plenty of goblet cells.</td>
</tr>
<tr>
<td>For hyperplastic or non-dysplastic crypts:</td>
<td>1</td>
<td>It can be identified by slightly dilated crypts and hypercellularity of slender, normal, uniform epithelium with enlarged nuclei, or by being sometimes crowded without stratification (Hamilton et al., 2000; Day et al., 2003; Cho et al., 2008). Otherwise, goblet cells appear normal with small, basally oriented nuclei and apical mucus localization.</td>
</tr>
<tr>
<td>For Mild to moderate dysplastic crypts</td>
<td>2</td>
<td>It is identified by slightly basophilic, enlarged and elongated crypts with increased crypt height. Cells exhibiting hypercellularity have dark, elongated (cigar-shaped) nuclei and focal nuclear stratification (between 1 and 1.5 nuclear heights) while maintaining their polarity. The cytoplasm of cells is less abundant than normal and contains less mucus. The mucus is extracellular in the crypt lumen or enclosed in tiny vacuoles (slightly fewer goblet cells).</td>
</tr>
<tr>
<td>For Moderate to severe dysplastic crypts</td>
<td>3</td>
<td>It is indicated by strongly basophilic crypts and increased crypt height. Elongated cells that exhibit hypercellularity and a lot of basophilic cytoplasm. Goblet cells are either significantly reduced or completely lost, resulting in very scant or absent intracellular mucus. Nuclear polarity is often lost. Larger rounded, or oval vesiculated nuclei, occasionally with noticeable nucleoli. In some areas, there is extensive nuclear stratification, which consists of two or more layers with numerous mitoses. There are a few nuclei that seem to be pleomorphic. Increased nuclear-to-cytoplasmic ratios and nuclear hyperchromasias are seen, and they extend to the mucosal surface (Hamilton et al., 2000; Day et al., 2003; Cho et al., 2008).</td>
</tr>
</tbody>
</table>

Since the crypts inspected in each field had different degrees of dysplasia; the crypt with the highest degree of dysplasia was used to determine the score.

Statistical analysis:
Statistical analyses were performed using the Statistical Package for Social Science program SPSS (version 16) software. The data are displayed as the mean ± SE. One-way analysis of variance (one-way ANOVA) was used to compare the data among the different experimental groups, and Turkey's multiple comparison method was then used to compare the means of the different groups. The Prism program, version 5.01 (Graph Pad Prism), was used to create the graphs, and the statistical significance level of acceptance was $P < 0.05$.

RESULTS

Effect of Nic and DMH on ACF formation and crypt multiplicity:
The effect of Nic and DMH on the ACF occurrence, total number of ACs, and crypt multiplicity (AC/ACF) were shown in Table 2 and Graph 1. The colonic tissue sections stained with Methylene blue showed the highest incidence of aberrant colonic crypt formation with unique morphology in the DMH group (349 ± 36) compared with colorectal tissue of the normal control group and Nic group (0 ± 0, $P <0.001$). Niclosamide-administered rats after DMH treatment (group IV) exhibited a significant decrease in the total number of ACF/rat (36 ±
when compared to rats treated with DMH (group III) (349 ± 36, p < 0.001). While the total number of ACF/rat significantly decreased in rats administered Nic with DMH treatment (group V) (17.6 ± 10, p < 0.01) when compared with Nic-administered rats after DMH treatment (group IV). The number of ACs was significantly reduced in group IV (276.6 ± 48.8) as compared to the DMH group (1684.6 ± 128, p < 0.001), but increased significantly when compared to group V (45.7 ± 11.6, p < 0.05). The number of AC/ACF (multiplicity) was 3.2 ± 0.1 in both groups IV and V, which was significantly lower as compared to that of 5 ± 0.5 in DMH (group III, p < 0.001). Group V showed a more significant reduction in both ACF and ACs (17.6 ± 10, 45.7 ± 11.6), respectively, as compared with DMH followed by the Nic group (group IV) (36 ± 15.8, 276.6 ± 48.8, p < 0.01).

Rats in both the control and Nic groups showed no signs of abnormalities with normal mucosal and submucosal layers (Fig. 3 A-B). On the other hand, DMH-treated rats exhibited moderate to severe dysplastic changes in the crypt epithelium. The dysplastic crypts were associated with lymphoid follicles in 90% of sections. Crypts with mild to moderate dysplasia were found in 2 rats out of 7. Dysplastic changes were indicated by hypercellularity and focal stratification of vesicular nuclei, with numerous mitotic figures limited to the lower half of the crypts and some apoptotic cells (Fig. 4A). Crypts with double-branched glands were also observed, which were lined with epithelium characterized by round to elongated hyperchromatic nuclei with depleted mucin that was contained in small vacuoles or located extracellularly in the crypt lumen (Fig. 4B). Five rats out of 7 showed severe dysplasia. Two of them showed serrated adenoma that was characterized by dilated and serrated crypts (saw-tooth structure) and intact muscularis mucosa (Fig. 4C). These crypts had large, hyperchromatic, elongated nuclei (displaying a pencillate pattern) arranged along the basement membrane in a stratified manner. There was loss of polarity, high nuclear/cytoplasmic ratio, increased basophilia of the cytoplasm, and the goblet cells were completely absent (Fig. 4D).

The administration of Nic after DMH (group IV) showed a significant decrease in the degree of dysplasia, which was mild to moderate. This was observed in 2 rats out of 7 and was characterized by slight dilatation of crypts with basally oriented elongated hyperchromatic nuclei and mild mucin depletion present in small vacuoles. There were numerous mitoses that may extend to the upper half of the crypts (Fig. 5 A-B). Hyperplastic crypts were observed in 5 rats out of 7 in the same group. In group V, where Nic was administered along with DMH treatment, the dysplastic changes were rarely observed as compared to groups III and IV, and the degree was mild to moderate, which
was found in one rat out of 7. The hyperplastic lesions were found in 3 rats out of 7. The remaining rats (3/7) exhibited more or less normal colonic mucosal crypts with goblet cells filled with mucin and basally oriented vesicular uniform ovoid nuclei with no crowding despite their presence above lymphoid aggregates (Fig. 5 C-D).

Table 2: Effect of Nic and DMH on ACF formation, AC count and crypt multiplicity

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. of rats</th>
<th>No. of ACF/rat</th>
<th>No. of AC/rat</th>
<th>NO. of AC/ACF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>7</td>
<td>0 ± 0 *</td>
<td>0 ± 0 a</td>
<td>0 ± 0 a</td>
</tr>
<tr>
<td>Nic group</td>
<td>7</td>
<td>0 ± 0 a</td>
<td>0 ± 0 a</td>
<td>0 ± 0 a</td>
</tr>
<tr>
<td>DMH group</td>
<td>7</td>
<td>349 ± 36 c</td>
<td>1684.6 ± 128 c</td>
<td>5 ± 0.5 c</td>
</tr>
<tr>
<td>DMH followed by Nic group</td>
<td>7</td>
<td>36 ± 15.8 b</td>
<td>276.6 ± 48.8 b</td>
<td>3.2 ± 0.1 b</td>
</tr>
<tr>
<td>DMH + Nic group</td>
<td>7</td>
<td>17.6 ± 10 a</td>
<td>45.7 ± 11.6 a</td>
<td>3.2 ± 0.1 b</td>
</tr>
</tbody>
</table>

Abbreviations: Nic = niclosamide, DMH = 1, 2-dimethylhydrazine, ACF = aberrant crypt foci, AC = aberrant crypt, AC/ACF = crypt multiplicity. Data is presented as means ± SE of 7 rats in each group. Groups not sharing a common superscript letter (a–c) differ significantly.

Graph 1. Abbreviations: Nic = niclosamide, DMH = 1, 2-dimethylhydrazine, ACF = aberrant crypt foci, AC = aberrant crypt, AC/ACF = crypt multiplicity. Data is presented as means ± SE of 7 rats in each group. Groups not sharing a common superscript letter (a–c) differ significantly.

Figure 1: Topographic view of the colon after mucosal staining with methylene blue showing normal crypts of control group (A) and Nic alone (B) treated animals (Bar=200).
Figure 2: Topographic view of the colons of DMH-administrated rats (A-B), DMH followed by Nic treated rats (C-D) and DMH + Nic treated rats (E-F). A: low power field showing five ACF with crypt multiplicity ranging from 2–8 AC/focus (black arrows) (bar=200). B: high power field showing a large focus with 9 AC/focus (white arrow) and a small focus with 2 AC/focus (black arrow) (bar=100). The lesion was slightly elevated, darkly stained, and had larger crypts with slit-shaped openings. C: low power field showing five small foci with low crypt multiplicity (1-2 AC/focus) (black arrows) (bar=200). D: high power field showing a small focus with 2 AC/focus (white arrow) (bar=100). F: low power field showing single doublet ACF (black arrows) (bar=200). E: high power field showing a small focus with 2 AC/focus (white arrow) (bar=100).

Table 3: The degree of dysplasia in different groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. of rats</th>
<th>Degree of dysplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>7</td>
<td>0 ± 0a</td>
</tr>
<tr>
<td>Nic group</td>
<td>7</td>
<td>0 ± 0a</td>
</tr>
<tr>
<td>DMH group</td>
<td>7</td>
<td>2.7 ± 0.2c</td>
</tr>
<tr>
<td>DMH followed by Nic group</td>
<td>7</td>
<td>1.3 ± 0.2b</td>
</tr>
<tr>
<td>DMH + Nic group</td>
<td>7</td>
<td>0.7 ± 0.3b</td>
</tr>
</tbody>
</table>

Abbreviations: Nic = niclosamide, DMH = 1, 2-dimethylhydrazine. All values displayed are mean ± SE. The groups that don’t have the same superscript are significantly different.
Graph 2: Abbreviations: Nic = niclosamide, DMH = 1, 2-dimethylhydrazine. All values displayed are mean ± SE. The groups that don't have the same superscript are significantly different.

Figure 3: The colon histology of untreated control rats (A) and rats that were given niclosamide (B) exhibiting straight, closely spaced, typical tubular crypts that extend to the muscularis mucosa and are rich in goblet cells (bar=100).

Figure 4: The colonic mucosa of DMH administrated rats shows mild to moderate dysplastic aberrant crypts (A-B). (A) The crypts show numerous mitoses limited to the lower half of the crypts (open black arrows) with slight mucin depletion (black arrows), apoptotic cells (curved red arrows) and focal stratification of vesicular nuclei (asterisk). (B) Some crypts have double-branching glands (crypt fission) (circle) (bar=20). (C) Traditional serrated adenoma with dilated and serrated crypts [saw-tooth structure] (black arrows) and intact Muscularis mucosa (bar=100). (D) A high-power view of dilated and serrated crypts with elongated hyperchromatic nuclei (displaying a pencillate pattern) (red arrow). The crypts show severe mucin depletion and stratification of nuclei (circles) (bar=20).
DISCUSSION

One of the most serious illnesses and a major global cause of cancer-related mortality is colorectal cancer (Hossain et al., 2022). Carcinogenesis is a multistep process, beginning with initiation followed by promotion and progression (Karthikkumar et al., 2015). Since human colon cancer is caused by a complex interplay of genetic and epigenetic events, DMH was utilized as a carcinogen in this study, which mimics the pathology of colon cancer in humans and does not only rely on extrapolating findings from in vitro models (Femia et al., 2010; Balaji et al., 2014). DMH-induced colon cancer develops through a sequence of pathological changes, from detached microscopic ACF mucosal lesions to malignant tumours (Muthu et al., 2016).

Aberrant crypt foci (ACF) are heterogeneous group of preneoplastic lesions of the adenoma-carcinoma sequence. They are identified in whole mounts of colon stained with methylene blue by abnormally shaped clusters of colonic crypts that begin as a single, bigger crypt with a thicker epithelial lining than typical crypts and then expand into larger clusters (Fayazfar et al., 2021). Numerous researchers have employed ACF as an early biomarker of colon carcinogenesis to assess the efficacy of different chemopreventive agents in a short-term model (Balaji et al., 2015; Rehman et al., 2018). According to Hirose et al. (2003), their emergence in rats with induced colon cancer indicates the initiation of colorectal carcinogenesis, and an increase in their number and crypt multiplicity correlates with the promotion and progression of carcinogenesis. Furthermore, their numbers and the multiplicities (crowding of crypts) are more indicative of malignant transformation and directly correspond with the risk of colon cancer, as in high-risk human cases (Wargovich et al., 2010). According to early research, ACF-inhibiting agents may also enhance the anticarcinogenicity in CRC.
models induced by carcinogens (Muthu et al., 2013). Hence, Nic was tested to find its anti-cancer efficacy at morphological and histopathological levels, which have previously shown anti-colon cancer activity in vitro and in xenograft tumour cells in vivo (Li et al., 2014; Satoh et al., 2016; Kang et al., 2021).

Niclosamide (Arend et al., 2016) is an oral anthelmintic drug that has been approved by the US FDA for treating most tapeworm infections in human and livestock for approximately 50 years (Andrews et al., 1982; Al-Hadiya 2005; Panahi et al., 2022). The Repurposing Drugs in Oncology (ReDO) project has identified a variety of antiparasitic medications as high-potential agents (Hu et al., 2013). Niclosamide is one of these medications, as reported by Wang et al. (2009).

In our study, we evaluated the effect of Nic on colon carcinogenesis in rats during the initiation and post-initiation (promotion) phases of colon cancer development. Taking into account a major endpoint of this study, the enumeration of the colonic morphological marker ACF. Crypt multiplicity and the total number of ACs were also calculated in addition to estimation of histopathological alterations. DMH alone treated rats had a noticeably greater incidence of ACF in their middle and distal colons (Aranganathan and Nalini 2013; Sharma et al., 2017). These findings are in line with earlier research, which also indicated that the distal colon had a higher incidence of colon cancer than the proximal colon (Liu and Xu 2008; Balaji et al., 2015).

Administration of Nic to DMH treated rats suppressed the ACF number, development and its multiplicity in contrast to what was found in the DMH group. Furthermore, Nic treatment along with DMH at the beginning of the experiment gave the most effective results (group V) (initiation stage) when compared with group IV that was treated with Nic after the DMH induction period (post-initiation stage). The suppressive effect of Nic against ACF induced by DMH is in line with what was found in a prior study that addressed Nic's ability to suppress early events of colon carcinogenesis (Sayed et al., 2023). That could be explained by Nic's possible antioxidant impact on the colon carcinogenesis induced by chemical carcinogens. It also has antiproliferative action in many human CRC cell lines (Kang et al., 2021). Consequently, our findings implied that Nic impedes colonic ACF development and prevents the conversion of preneoplasia to malignant neoplasia.

The histopathological observations in this study revealed no anomalies in crypt morphology and architecture in the control and Nic groups. However, there was a range of pathological abnormalities in the colon tissue after administration of DMH, including aberrant crypt formation, depletion of mucin, numerous mitosis, and hyperchromatic nuclei along with dysplasia of high grade. Dysplastic rather than hyperplastic crypts are more associated with a higher malignancy incidence (Clapper et al., 2020).

However, there was an improvement in the colon histopathological status upon treatment with Nic, reducing the degree of dysplasia in aberrant crypts, which can be attributed to the chemopreventive potential of Nic. We discovered that the observed damage was more improved in group V as it had a brought back histo-architecture, which resembles that of a normal colon, confirming the potent protective role of Nic against colon carcinogenesis when administered with DMH in the initial stage. This research revealed that Nic had a suppressive and protective effect on the early stages of colorectal cancer development. This has been confirmed by other studies that examined Nic's anticancer activity by inhibiting several pathways that are aberrantly activated in these stages of carcinogenesis in both in vitro and in vivo models (Li et al., 2014; Satoh et al., 2016). Some of these pathways include Wnt/β-catenin, which is hyperactive in 80% of
patients with sporadic CRC. Stat3, mTORC1, NF-kB and Notch signaling pathways (Wieland et al., 2013; Londono-Joshi et al., 2014; You et al., 2014; Arend et al., 2016). In addition to inhibiting all of these pathways, which is essential for Nic’s anti-proliferative action, Nic targets the mitochondria of cancer cells to induce apoptosis, growth inhibition and cell cycle arrest, making it a potentially effective anticancer agent (Ye et al., 2014; Satoh et al., 2016).

This multi-targeted property of Nic makes it an effective supportive treatment with other basic therapies in colon cancer treatment. In chemotherapy-resistant cells, it demonstrated a strong anti-proliferative effect against cancer cells (Chen et al., 2010; Osada et al., 2011; Mook et al., 2013). It could also be used as prophylactic treatment, especially in patients with high risk of CRC, such as those with hereditary syndromes (e.g., FAP and Lynch syndrome) and people with a familial history of colorectal polyps or CRC. Additionally, Nic demonstrated no detectable toxicity on non-cancerous cells in vitro, while Nic-treated mice showed no adverse effects (Mook et al., 2015; Mook et al., 2017; Chen et al., 2018; Wang et al., 2018). The clinical trials registry included multiple Nic clinical trials for prostate and colon cancer (Chen et al., 2018). It was proposed that individuals would not experience cumulative adverse effects from long-term exposure to Nic (Andrews et al., 1982). So it could be used safely in a long-term treatment course.

CONCLUSION

This study aimed to confirm and evaluate the anticancer effect of Nic on colon carcinogenesis in a DMH-induced colon cancer animal model. This was indicated by a significantly lower incidence of ACF, ACs, and crypt multiplicity in the middle and distal colon in both Nic-treated groups. Nic reduced the DMH-induced histopathological lesions by decreasing the degree of dysplasia from severe to mild. These alterations were significantly lower in the initiation stage of CRC development in comparison to the post-initiation stage, which confirms the potent anticarcinogenic efficacy of Nic against colon carcinogenesis and makes it a preventive agent that impedes the progression of preneoplastic lesions to neoplasia. However, more studies will be required to determine its clinical value as a prophylactic and supportive treatment and learn more about its possible role in the advanced stages of colorectal cancer.

REFERENCE


signaling. PloS One, 4(9), e7124.


Can anti...–.

Satoh, K., Zhang, L., Zhang, M.A.M.; Silva, L.A.G.; Salvadori, D.

Okda, T. M., Abd El-Aziz, M. A., El-Melegy, N.


Rodrigues, M.A.M.; Silva, L.A.G.; Salvadori, D.


التأثير المضاد للأورام للنيكلوساميد على سرطان القولون والمستقيم المستحث تجريبياً في الجرذان

سمر سليمان خلف، ساري خليل عبد الغفار، مروة فاروق

Email: samar_soliman@vet.aun.edu.eg  Assiut University web-site: www.aun.edu.eg

من الأدوات البحثية الأساسية لدراسة سرطان القولون والمستقيم (CRC) استخدام ١ و ٢-ثنائي ميثيل الهيدرازين (DMH) كنموذج حيوي. تم تحديد النكليكساميد، وهو دواء مضاد للديدان عن طريق الفم، كعامل محتمل مضاد للسرطان. تهدف هذه الدراسة إلى تحديد التأثير المحتمل للمضادات للأورام للنكلوساميد على السرطان في القولون والمستقيم. تم تقسيم خمسة جرذان إلى خمس مجموعات. تم إعطاء المجموعة الأولى (I) المذيب لمدة ٤ أسابيع. تلقت المجموعة الثانية (II) النكليكساميد عن طريق الحقن داخل الصفاق (I/P) بجرعة ٢٠ ملجم/كجم من وزن الجسم يومياً لمدة ٤ أسابيع. تم إعطاء المجموعة الثالثة (III) حقن تحت الجلد (S/C) من DMH بجرعة ٢٠ ملجم/كجم من وزن الجسم مرتين في الأسبوع لمدة ٤ أسابيع. المجموعة الرابعة (IV) والخامسة (V) تلقت DMH أولاً كما في المجموعة الثالثة، وبعد أسبوع واحد من آخر حقن DMH تلقت في المجموعة الثانية (II) النكليكساميد عن طريق الحقن داخل الصفاق (I/P) بجرعة ٢٠ ملجم/كجم من وزن الجسم يومياً حتى نهاية التجربة. تلقت المجموعة الخامسة (V) النكليكساميد عن طريق الحقن S/C بجرعة ٢٠ ملجم/كجم من وزن الجسم يومياً، وفي الوقت نفسه، تم إعطاء المجموعة الرابعة (IV) حقن تحت الجلد (S/C) من DMH بجرعة ٢٠ ملجم/كجم من وزن الجسم يومياً لمدة أربعة أسابيع. في نهاية التجربة التي استمرت ٢١ أسبوعاً، تم نزول الجرذان، ثم تخزين جزء من كل مجموعة لحساب بؤرات التجويف الشاذة (ACF) باستخدام ٢٠٪ أزرق الميثيلين. تم أخذ عينات القولون من كل المجموعات لفحصها النسيجي. وفقاً للسمات الطبوغرافية لآفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغيرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغيرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم أخذ عينات النسيج عند نهاية التجربة، ودقيقتها النسيجية. وفقاً للسمات الطبوغرافية لأفات ما قبل الورم في القولون، وجدونا أن المجموعة الثالثة لديها تغييرات معنوية من أدنى مستويات أياً من المجموعات. وتم ا